Indaptus Therapeutics closed at $3.30 on Nov 4, up 1.85%, 30.5% below its 52-week closing high. Volume of 111.4K shares was 0.30× its 20-day average (below normal).
Split-adjusted performance: +27.4% over one month, +61.0% over six months, +5.8% over one year.
Short interest was 856.7K shares at the Oct 15 settlement, up 4.2% from the prior report (7.4% of float, 1.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| INDPIndaptus Therapeutics | $3.30 | +1.85% | +61.0% | — | — | — | $439.7M | |
| CRMDCorMedix | $5.66 | +1.80% | −29.7% | +156.5% | 25.5% | 2.4 | $441.2M | Compare |
| TLRYTilray Brands | $2.96 | +11.70% | −48.6% | +22.7% | −16.8% | — | $437.5M | Compare |
| RLMDRelmada Therapeutics | $4.17 | −2.34% | −46.9% | — | — | — | $444.8M | Compare |
| PRTAProthena | $8.39 | +2.19% | −25.0% | −77.1% | −1839.9% | — | $430.7M | Compare |
| PHATPhathom Pharmaceuticals | $5.68 | −1.05% | −55.2% | +71.1% | −16.4% | — | $461.7M | Compare |
| ALTAltimmune | $2.12 | +3.92% | −35.0% | −100.0% | — | — | $412.4M | Compare |
| GYREGyre Therapeutics | $4.44 | 0.00% | −44.8% | −2.1% | −40.1% | — | $470.8M | Compare |
| AQSTAquestive Therapeutics | $3.80 | −2.06% | −10.2% | +38.1% | −165.5% | — | $476.9M | Compare |
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
